13 extractive question-and-answer pairs built from ICMR Standard Treatment Workflow (STW) LUNG CANCER, published by icmr.gov.in. The source is a 1-page publication. Source-evidenced topics include lung cancer, oral tki, platinum doublet, mri brain, after treating pneumonia, available treatment options, important assessment parameters, lung resection- lobectomy. Every answer is a verbatim span of text the source prints, and each row carries the passage it sits in, its offset in that passage, the source quote, the page and the location in the document, so any row can be checked against the original. Question types in the export: 9 list, 2 factual, 2 summary. 11 of the 13 pairs (84.6%) ask explanatory questions; the remaining 2 are factual or table-based questions. 100.00% of rows pass the corpus quality gate.
This dataset contains 13 extractive question-and-answer pairs derived from the ICMR Standard Treatment Workflow (STW) for lung cancer. The source material is a single-page publication from icmr.gov.in, addressing topics such as treatment options, diagnostic procedures, and assessment parameters for lung cancer. Questions include lists, factual queries, and summaries, with answers directly quoted from the source. The dataset provides insights into clinical practices, including palliation, molecular testing, and histopathological analysis.
Browse more health datasets, including other records from the same source when available.
Explore Health datasets1725952331_psychiatry_all - Question and Answer Dataset
Economy · 176 rows
ICMR Standard Treatment Workflow (STW) SUPRACONDYLAR FRACTURE OF HUMERUS IN CHILDREN - Question and Answer Dataset
Economy · 22 rows
1726569102_ophthalmology_all - Question and Answer Dataset
Health · 77 rows
1725952349_ent - Question and Answer Dataset
Health · 178 rows
NFHS-5 Dataset
Health · 3.8K+ rows
National Health Profile 2022 - Question and Answer Dataset
Health · 5.7K+ rows
National Health Profile 2022 — Question and Answer Dataset
Health · 5.7K+ rows
XVFC VOL I Main Report - Question and Answer Dataset
Health · 1.7K+ rows
Use the API URL with your free DD token in notebooks, scripts, and pipelines.
https://www.desidata.in/api/datasets/www-icmr-gov-in-7f630a7e31d7fb7e9f12ac610f7d9e63/downloadDataset downloads are free. For Python or API downloads, sign in once and create a free DD token; set it as DD_TOKEN or save it in your notebook's secrets. Requests are linked to your account so your download history and counts stay accurate.
# One-time install: pip install desidata
# Set DD_TOKEN in your environment first (create a free token in Profile & settings).
import desidata
df = desidata.load("www-icmr-gov-in-7f630a7e31d7fb7e9f12ac610f7d9e63")
df.head()First 10 of 13 rows
| question | answer | context | answer_start | question_type | knowledge_quality_score | source_document | source_quote | source_page | source_location | confidence | validation_status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| What treatment is suggested for patients unfit or refusing surgery? | Pallative radiation; Bisphosphonates for bone metastases | Early localized : T1-3, N0-2 Locoregionally advanced : T4, N3 Metastatic disease. any T, any N, M1 Concurrent CT+ RT Brain/ symptomatic bone metastases Other visceral metastases EBUS/ EUS ± mediastinoscopy Unfit or patient refuses surgery Pallative radiation; Bisphosphonates for bone metastases Histology Oral TKI or platinum doublet chemotherapy Platinum doublet chemotherapy or chemoimmunotherapy Non- Squamous Squamous carcinoma Mutation +ve Mutation -ve Driver mutation test Platinum doublet chemotherapy or chemoimmunotherapy | 239 | summary | 0.970 | https://www.icmr.gov.in/icmrobject/uploads/STWs/1726568902_lung_cancer.pdf | any T, any N, M1 Concurrent CT+ RT Brain/ symptomatic bone metastases Other visceral metastases EBUS/ EUS ± mediastinoscopy Unfit or patient refuses surgery Pallative radiation; Bisphosphonates for bone metastases Histology Oral TKI or platinum doublet chemotherapy Platinum doublet chemotherapy or chemoimmunotherapy Non- Squamous Squamous carcinoma Mutation +ve Mutation -ve Driver mutation test Platinum doublet chemotherapy or chemoimmunotherapy | 1 | page=1,block=42 | 0.700 | valid |
| What care options are mentioned besides chemotherapy and immunotherapy? | Symptomatic & supportive care | Biopsy/ cell block/ smear • Histopathology adenocarcinoma, squamous carcinoma, poorly differentiated carcinoma, small cell carcinoma • Immunohistochemistry TTF 1, p40, synaptophysin/ chromogranin • Preserve tissue for molecular analysis Molecular tests for adenocarcinoma: EGFR, ALK, ROS-1 • Symptomatic & supportive care • Refer to oncology centre • Palliative chemotherapy (platinum doublet in fit patients, single agent chemotherapy for PS 2) • Oral TKI if target mutation detected • Immunotherapy may be an option in some patients | 292 | summary | 0.890 | https://www.icmr.gov.in/icmrobject/uploads/STWs/1726568902_lung_cancer.pdf | Biopsy/ cell block/ smear • Histopathology adenocarcinoma, squamous carcinoma, poorly differentiated carcinoma, small cell carcinoma • Immunohistochemistry TTF 1, p40, synaptophysin/ chromogranin • Preserve tissue for molecular analysis Molecular tests for adenocarcinoma: EGFR, ALK, ROS-1 • Symptomatic & supportive care • Refer to oncology centre • Palliative chemotherapy (platinum doublet in fit patients, single agent chemotherapy for PS 2) • Oral TKI if target mutation detected • Immunotherapy may be an option in some patients | ||||
| What are some symptoms or findings assessed during clinical examination? | Palpable lymph nodes • Chest wall tenderness • Skeletal tenderness • Pleural effusion | • Metastatic disease Any T, any N, M1 • Non metastatic disease T1-4, N0-3, M0 Do CECT thorax and abdomen • Prophylactic cranial irradiation • Symptomatic & supportive care • Palliative chemotherapy carboplatin + etoposide Clinical examination: • Palpable lymph nodes • Chest wall tenderness • Skeletal tenderness • Pleural effusion IMPORTANT ASSESSMENT PARAMETERS PRESENTATION Age and comorbidities Performance status | 246 | list | 0.820 | https://www.icmr.gov.in/icmrobject/uploads/STWs/1726568902_lung_cancer.pdf | • Metastatic disease Any T, any N, M1 • Non metastatic disease T1-4, N0-3, M0 Do CECT thorax and abdomen • Prophylactic cranial irradiation • Symptomatic & supportive care • Palliative chemotherapy carboplatin + etoposide Clinical examination: • Palpable lymph nodes • Chest wall tenderness • Skeletal tenderness • Pleural effusion IMPORTANT ASSESSMENT PARAMETERS PRESENTATION Age and comorbidities Performance status | 1 | page=1,block=11 | 0.700 | valid |
| What are the important assessment parameters for presentation? | Age and comorbidities Performance status | • Metastatic disease Any T, any N, M1 • Non metastatic disease T1-4, N0-3, M0 Do CECT thorax and abdomen • Prophylactic cranial irradiation • Symptomatic & supportive care • Palliative chemotherapy carboplatin + etoposide Clinical examination: • Palpable lymph nodes • Chest wall tenderness • Skeletal tenderness • Pleural effusion IMPORTANT ASSESSMENT PARAMETERS PRESENTATION Age and comorbidities Performance status | 377 | list | 0.820 | https://www.icmr.gov.in/icmrobject/uploads/STWs/1726568902_lung_cancer.pdf | • Metastatic disease Any T, any N, M1 • Non metastatic disease T1-4, N0-3, M0 Do CECT thorax and abdomen • Prophylactic cranial irradiation • Symptomatic & supportive care • Palliative chemotherapy carboplatin + etoposide Clinical examination: • Palpable lymph nodes • Chest wall tenderness • Skeletal tenderness • Pleural effusion IMPORTANT ASSESSMENT PARAMETERS PRESENTATION Age and comorbidities Performance status | 1 | page=1,block=11 | 0.700 | valid |
| What diagnostic procedures are mentioned for pleural fluid analysis? | Pleural fluid cytology • Pleural biopsy (image guidance if available) | WHEN TO SUSPECT Pulmonary function CXR Sputum cytology Pulmonary reserve: • Effort tolerance • Walk test • Pulmonary function tests (PFT) • Cough • Chest pain • Hemoptysis • Hoarseness • Breathlessness • Non resolving pneumonia • Mass lesion • Symptoms persist even after treating pneumonia • Pleural fluid cytology • Pleural biopsy (image guidance if available) • Cervical lymph node aspiration cytology / biopsy | 293 | list | 0.820 | https://www.icmr.gov.in/icmrobject/uploads/STWs/1726568902_lung_cancer.pdf | WHEN TO SUSPECT Pulmonary function CXR Sputum cytology Pulmonary reserve: • Effort tolerance • Walk test • Pulmonary function tests (PFT) • Cough • Chest pain • Hemoptysis • Hoarseness • Breathlessness • Non resolving pneumonia • Mass lesion • Symptoms persist even after treating pneumonia • Pleural fluid cytology • Pleural biopsy (image guidance if available) • Cervical lymph node aspiration cytology / biopsy | 1 | page=1,block=25 | 0.700 | valid |
| What tests are used to assess pulmonary reserve? | Effort tolerance • Walk test • Pulmonary function tests (PFT) | WHEN TO SUSPECT Pulmonary function CXR Sputum cytology Pulmonary reserve: • Effort tolerance • Walk test • Pulmonary function tests (PFT) • Cough • Chest pain • Hemoptysis • Hoarseness • Breathlessness • Non resolving pneumonia • Mass lesion • Symptoms persist even after treating pneumonia • Pleural fluid cytology • Pleural biopsy (image guidance if available) • Cervical lymph node aspiration cytology / biopsy | 76 | list | 0.820 | https://www.icmr.gov.in/icmrobject/uploads/STWs/1726568902_lung_cancer.pdf | WHEN TO SUSPECT Pulmonary function CXR Sputum cytology Pulmonary reserve: • Effort tolerance • Walk test • Pulmonary function tests (PFT) • Cough • Chest pain • Hemoptysis • Hoarseness • Breathlessness • Non resolving pneumonia • Mass lesion • Symptoms persist even after treating pneumonia • Pleural fluid cytology • Pleural biopsy (image guidance if available) • Cervical lymph node aspiration cytology / biopsy | 1 | page=1,block=25 | 0.700 | valid |
| What type of carcinoma can be identified using histopathology? | adenocarcinoma, squamous carcinoma, poorly differentiated carcinoma, small cell carcinoma | Biopsy/ cell block/ smear • Histopathology adenocarcinoma, squamous carcinoma, poorly differentiated carcinoma, small cell carcinoma • Immunohistochemistry TTF 1, p40, synaptophysin/ chromogranin • Preserve tissue for molecular analysis Molecular tests for adenocarcinoma: EGFR, ALK, ROS-1 • Symptomatic & supportive care • Refer to oncology centre • Palliative chemotherapy (platinum doublet in fit patients, single agent chemotherapy for PS 2) • Oral TKI if target mutation detected • Immunotherapy may be an option in some patients | 43 | list | 0.820 | https://www.icmr.gov.in/icmrobject/uploads/STWs/1726568902_lung_cancer.pdf | Biopsy/ cell block/ smear • Histopathology adenocarcinoma, squamous carcinoma, poorly differentiated carcinoma, small cell carcinoma • Immunohistochemistry TTF 1, p40, synaptophysin/ chromogranin • Preserve tissue for molecular analysis Molecular tests for adenocarcinoma: EGFR, ALK, ROS-1 • Symptomatic & supportive care • Refer to oncology centre • Palliative chemotherapy (platinum doublet in fit patients, single agent chemotherapy for PS 2) • Oral TKI if target mutation detected • Immunotherapy may be an option in some patients | ||||
| What symptoms might indicate a pulmonary issue? | Cough • Chest pain • Hemoptysis • Hoarseness • Breathlessness | WHEN TO SUSPECT Pulmonary function CXR Sputum cytology Pulmonary reserve: • Effort tolerance • Walk test • Pulmonary function tests (PFT) • Cough • Chest pain • Hemoptysis • Hoarseness • Breathlessness • Non resolving pneumonia • Mass lesion • Symptoms persist even after treating pneumonia • Pleural fluid cytology • Pleural biopsy (image guidance if available) • Cervical lymph node aspiration cytology / biopsy | 140 | list | 0.780 | https://www.icmr.gov.in/icmrobject/uploads/STWs/1726568902_lung_cancer.pdf | WHEN TO SUSPECT Pulmonary function CXR Sputum cytology Pulmonary reserve: • Effort tolerance • Walk test • Pulmonary function tests (PFT) • Cough • Chest pain • Hemoptysis • Hoarseness • Breathlessness • Non resolving pneumonia • Mass lesion • Symptoms persist even after treating pneumonia • Pleural fluid cytology • Pleural biopsy (image guidance if available) • Cervical lymph node aspiration cytology / biopsy | 1 | page=1,block=25 | 0.700 | valid |
| Which immunohistochemistry markers are mentioned for analysis? | TTF 1, p40, synaptophysin/ chromogranin | Biopsy/ cell block/ smear • Histopathology adenocarcinoma, squamous carcinoma, poorly differentiated carcinoma, small cell carcinoma • Immunohistochemistry TTF 1, p40, synaptophysin/ chromogranin • Preserve tissue for molecular analysis Molecular tests for adenocarcinoma: EGFR, ALK, ROS-1 • Symptomatic & supportive care • Refer to oncology centre • Palliative chemotherapy (platinum doublet in fit patients, single agent chemotherapy for PS 2) • Oral TKI if target mutation detected • Immunotherapy may be an option in some patients | 156 | list | 0.780 | https://www.icmr.gov.in/icmrobject/uploads/STWs/1726568902_lung_cancer.pdf | Biopsy/ cell block/ smear • Histopathology adenocarcinoma, squamous carcinoma, poorly differentiated carcinoma, small cell carcinoma • Immunohistochemistry TTF 1, p40, synaptophysin/ chromogranin • Preserve tissue for molecular analysis Molecular tests for adenocarcinoma: EGFR, ALK, ROS-1 • Symptomatic & supportive care • Refer to oncology centre • Palliative chemotherapy (platinum doublet in fit patients, single agent chemotherapy for PS 2) • Oral TKI if target mutation detected • Immunotherapy may be an option in some patients | ||||
| What diagnostic procedures are mentioned for mediastinal evaluation? | EBUS/ EUS ± mediastinoscopy | Early localized : T1-3, N0-2 Locoregionally advanced : T4, N3 Metastatic disease. any T, any N, M1 Concurrent CT+ RT Brain/ symptomatic bone metastases Other visceral metastases EBUS/ EUS ± mediastinoscopy Unfit or patient refuses surgery Pallative radiation; Bisphosphonates for bone metastases Histology Oral TKI or platinum doublet chemotherapy Platinum doublet chemotherapy or chemoimmunotherapy Non- Squamous Squamous carcinoma Mutation +ve Mutation -ve Driver mutation test Platinum doublet chemotherapy or chemoimmunotherapy | 178 | list | 0.740 | https://www.icmr.gov.in/icmrobject/uploads/STWs/1726568902_lung_cancer.pdf | any T, any N, M1 Concurrent CT+ RT Brain/ symptomatic bone metastases Other visceral metastases EBUS/ EUS ± mediastinoscopy Unfit or patient refuses surgery Pallative radiation; Bisphosphonates for bone metastases Histology Oral TKI or platinum doublet chemotherapy Platinum doublet chemotherapy or chemoimmunotherapy Non- Squamous Squamous carcinoma Mutation +ve Mutation -ve Driver mutation test Platinum doublet chemotherapy or chemoimmunotherapy | 1 | page=1,block=42 |
Read straight from the file — download or use the API URL for the full dataset.
| 1 |
| page=1,block=4 |
| 0.700 |
| valid |
| 1 |
| page=1,block=4 |
| 0.700 |
| valid |
| 1 |
| page=1,block=4 |
| 0.700 |
| valid |
| 0.700 |
| valid |